Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

CA25253X2077
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000LP4YD7
DMAC
DiaMedica Therapeutics, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
DiaMedica Therapeutics, Inc.
ISIN
CA25253X2077
TICKER
DMAC
MIC
XNAS
REUTERS
DMAC.OQ
BLOOMBERG
DMAC US
Di., 04.08.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its second quarter 2026 financial results will be released after the markets close on Monday, August 10th. DiaMedica will host...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.07.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on July 15, 2026, it granted options to purchase an aggregate of 160,000 shares of DiaMedica’s common stock to a newly hired non-exe...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 23.06.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 (rinvecalinase alfa) for the treatment of fetal gro...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding the need for additional nonclinical reproductive toxicity data to support continued development of DM199 (rinvecalinase alfa) for the treatment of...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 27.05.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held in New York on June 2-4 2026. Jefferies Global H...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 20.05.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and fetal growth restriction, today announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in patients with acute ischemic stroke (AIS) has rea...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 12.05.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that its President and CEO, Rick Pauls, will participate in a fireside chat at the upcoming 2026 RBC Capital Markets Global Healthcare Co...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 06.05.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today provided a business update and reported financial results for the quarter ended March 31, 2026. Management will host a conference...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6th. DiaMedica will host a...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       DiaMedica Therapeutics
CA25253X2077

ORLANDO, FL / ACCESS Newswire / April 7, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual investor conference, Biotech Resurgence: Platforms and Pipelines of Today's Innovators, taking place April 16, 2026, from 9:30 a.m. to 4:00 p.m. E...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 30.03.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS), today provided a business update and reported financial results for the year ended December 31, 2025. Management will host a conference...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 23.03.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its full-year 2025 financial results will be released after the markets close on Monday, March 30th. DiaMedica will host a liv...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to evaluate DM199 in a Phase...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conferences. Details TD Cowen 46th Annual Healthcare Confe...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 16.01.2026       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 shares of DiaMedica’s common stock to a newly hired non-e...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 18.12.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced completion of a productive in-person pre-IND meeting with the United States Food and Drug Administration (FDA) for a planned study...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 12.11.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction and acute ischemic stroke (AIS), today provided a business update and reported financial results for the third quarter ended September 30, 2025. Management will host a confere...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 10.11.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, will participate in the Jefferies Global Healthcare Conference in London, taking place November 17-20...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third quarter 2025 financial results will be released after the markets close on Wednesday, November 12th. DiaMedica will host a live conference call on T...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 29.09.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on September 18, 2025, it granted stock options to purchase an aggregate of 490,000 shares of DiaMedica’s common stock to five newly...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 05.09.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will participate in two upcoming investor conferences in N...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 02.09.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will participate in a fireside chat at the upcoming Cantor...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 12.08.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2025. Management will host a conference call Wednes...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 23.07.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the closing of its previously announced $30.1 million private placement of common shares to accredited investors. The Company sold approx...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 21.07.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced definitive agreements for a $30.1 million private placement of common shares led by current investors. No placement agent was engaged for...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 17.07.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia. The study achieved pre-specified safety and efficacy endpoints for the Part 1a dose escalation phase, reinforcing the therapeutic potential of...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 24.06.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27. The Russell 3000...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 22.05.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will present at the upcoming Jefferies Global Healthcare Conference, being held in Ne...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 19.05.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, May 28, 2025, at 8:00 AM ET to provide further insight into the current treatment landscape of preeclampsia and the...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 14.05.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of the safety and clinical outcomes for ReMEDy2 study, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the 11th European Stroke Organisati...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 13.05.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the quarter ended March 31, 2025. Management will host a conference call Wednesday, May 14, 2025, at 8:00 AM Eastern Tim...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 08.05.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025. 2025 RBC Capital Markets Global Healthcare Conference Tuesday, May 20th – Wednesday, May 21st, 2...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesda...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 17.03.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, March 18, 2025, at 8:00 AM Eastern Tim...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 11.03.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its full-year 2024 financial results will be released after the markets close on Monday, March 17th. DiaMedica will host a live conference call on Tuesday, March 18th at 7:...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 24.02.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O’Connor to its Board of Directors, effective February 20, 2025. Mr. O’Connor has decades of executive experience and leadership in the biopharmaceutical industry, inc...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 20.02.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed publication entitled: Recombinant human tissue kallikrein-1 for treating acute ischemic stroke and preventing recurrence (Kasner, et al.) which is now availabl...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 10.02.2025       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025 at 11:20am Eastern Time. Investors and att...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 03.12.2024       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, is excited to announce the formation of its Scientific Advisory Board (SAB) to support the development of DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia (...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 13.11.2024       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended September 30, 2024. Management will host a conference call Thursday, November 14, 2024, at 8:00 AM Eastern Time / 7:...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 13.11.2024       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first patient has been dosed in DiaMedica’s investigator-sponsored Phase 2 trial of DM199 for the treatment of preeclampsia (PE). DiaMedica anticipates top line data fo...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 12.11.2024       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be avail...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 06.11.2024       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its third quarter 2024 financial results will be released after market close on Wednesday, November 13th. DiaMedica will host a live conference call on Thursday, November 1...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.10.2024       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been received to initiate a Phase 2 clinical trial with DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia. The South...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 04.09.2024       DiaMedica Therapeutics
CA25253X2077

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke and preeclampsia, announced today that management will be participating in the following investor conferences during September. HC Wainwright Global Investment...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 21.07.2022       DiaMedica Therapeutics
CA25253X2077

Toronto, Ontario--(Newsfile Corp. - July 21, 2022) - On July 8, 2022, Thomas Von Koch (the "Acquiror"), c/o EQT Partners AB, Box 16509, 103 27 Stockholm, Sweden, acquired indirect ownership, through TomEnterprise AB, of an aggregate of 304,827 common shares (the "Purchased Shares") of DiaMedica Therapeutics Inc. (the "Issuer") through the facilitie...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 21.07.2022       DiaMedica Therapeutics
CA25253X2077

Toronto, Ontario--(Newsfile Corp. - July 21, 2022) - Thomas Von Koch (the "Acquiror"), c/o EQT Partners AB, Box 16509, 103 27 Stockholm, Sweden, acquired indirect ownership, through TomEnterprise AB, of an aggregate of 304,827 common shares (the "Purchased Shares") of DiaMedica Therapeutics Inc. (the "Issuer") through the facilities of The NASDAQ C...
Zur Nachricht
DiaMedica Therapeutics
Charts & Research Termsheets Terminal
Permalink